The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/154949

Please be advised that this information was generated on 2017-08-24 and may be subject to change.
**Deficiency of ECHS1 causes mitochondrial encephalopathy with cardiac involvement**

Tobias B. Haack1,2,a, Christopher B. Jackson3, Kei Murayama4, Laura S. Kremer1,2, André Schaller5, Urania Kotzaeridou6, Maaike C. de Vries7, Gudrun Schottmann8, Saikat Santra9, Boriana Büchner10, Thomas Wieland11,12, Elisabeth Graf1,2, Peter Freisinger11, Sandra Eggimann11, Akira Ohtake12, Yasushi Okazaki13,14, Masakazu Kohda13, Yoshihiro Kishita14, Yoshihiro Tokuzawa14, Sascha Sauer15, Yasin Memari16, Anja Kolb-Kokocinski16, Richard Durbin16, Oswald Hasselmann17, Kirsten Cremer18, Beate Albrecht19, Dagmar Wieczorek19, Hartmut Engels18, Dagmar Hahn3, Alexander M. Zink18, Charlotte L. Alston20, Robert W. Taylor20, Richard J. Rodenburg7, Regina Trollmann21, Wolfgang Sperl22, Tim M. Strom1,2, Georg F. Hoffmann8, Johannes A. Mayr22, Thomas Meitinger1,2,23,24, Ramona Bolognini5, Markus Schuelke8, Jean-Marc Nuoffer3,a, Stefan Kölder6,a, Holger Prokisch1,2,a, & Thomas Kloppstock10,23,24,a

1Institute of Human Genetics, Technische Universität München, 81675, Munich, Germany
2Institute of Human Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764, Neuherberg, Germany
3Institute of Clinical Chemistry and University Children's Hospital, University of Bern, 3010, Bern, Switzerland
4Department of Metabolism, Chiba Children's Hospital, Chiba, 266-0007, Japan
5Division of Human Genetics, Department of Pediatrics, University of Bern, 3010, Bern, Switzerland
6Divisions of Inherited Metabolic Disease and Neuropediatrics, Department of General Pediatrics, University Hospital Heidelberg, D-69120, Heidelberg, Germany
7Department of Pediatrics, Nijmegen Center for Mitochondrial Disorders, Radboud University Center, 6525 GA, Nijmegen, The Netherlands
8Department of Neuropediatrics and NeuroCure Clinical Research Center, Charité Universitätsmedizin Berlin, 13353, Berlin, Germany
9Department of Pediatrics, Birmingham Children's Hospital, Birmingham, B4 6NH, United Kingdom
10Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University, 80336, Munich, Germany
11Department of Pediatrics, Klinikum Reutlingen, 72764, Reutlingen, Germany
12Department of Pediatrics, Faculty of Medicine, Saitama Medical University, Saitama, 350-0495, Japan
13Division of Translational Research, Research Center for Genomic Medicine, Saitama Medical University, Saitama, 350-1241, Japan
14Division of Functional Genomics & Systems Medicine, Research Center for Genomic Medicine, Saitama Medical University, Saitama, 350-1241, Japan
15Max-Planck-Institute for Molecular Genetics, Otto-Warburg Laboratory, 14195, Berlin, Germany
16Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
17Department of Neuropediatrics, Children’s Hospital of Eastern Switzerland St.Gallen, 9006, St. Gallen, Switzerland
18Institute of Human Genetics, University of Bonn, 53127, Bonn, Germany
19Institut für Humangenetik, Universitätssklinikum Essen, Universität Duisburg-Essen, 45122, Essen, Germany
20Wellcome Trust Centre for Mitochondrial Research, Institute of Neuroscience, The Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH, United Kingdom
21Department of Pediatrics, Friedrich-Alexander-University of Erlangen-Nürnberg, 91054, Erlangen, Germany
22Department of Pediatrics, Parkacels Medical University Salzburg, 5020, Salzburg, Austria
23Munich Cluster for Systems Neurology (SyNergy), 80336, Munich, Germany
24DZNE – German Center for Neurodegenerative Diseases, 80336, Munich, Germany

**Correspondence**

Holger Prokisch, Institute of Human Genetics, Technische Universität München, Klinikum rechts der Isar, Trogenerstr. 32, 81675 Munich, Germany. Tel: +49 89 3197 2890; Fax: +49 89 3187 3297; E-mail: prokisch@helmholtz-muenchen.de and Thomas Kloppstock, Department of Neurology, Friedrich-Baur-Institute, University of Munich, Ziemssenstr. 1, 80336 Munich, Germany. Tel: +49-89-4400-57400, Fax: +49-89-4400-57402, E-mail: tkloppsto@med.lmu.de

**Abstract**

**Objective:** Short-chain enoyl-CoA hydratase (ECHS1) is a multifunctional mitochondrial matrix enzyme that is involved in the oxidation of fatty acids and essential amino acids such as valine. Here, we describe the broad phenotypic spectrum and pathobiochemistry of individuals with autosomal-recessive ECHS1 deficiency. **Methods:** Using exome sequencing, we identified ten unrelated individuals carrying compound heterozygous or homozygous mutations in ECHS1. Functional investigations in patient-derived fibroblast cell lines included immunoblotting, enzyme activity measurement, and a palmitate loading assay. **Results:** Patients showed a heterogeneous phenotype with disease
Funding Information

This study was supported by the European Commission (FP7/2007-2013, under grant agreement number 262055 \[ESGI\], as a Transnational Access project of the European Sequencing and Genotyping Infrastructure); by the German Bundesministerium für Bildung und Forschung (BMBF) through the E-Rare project GENOMIT (01GM1207 for T. M. and H. P. and PWF | 920-B13 for J. A. M.), the German Network for Mitochondrial Disorders (mitoNET, 01GM1113A to B. B. and T. K., 01GM1113C to T. M., H. P. and P. F., and 01GM1113D to M. S.), the German Mental Retardation Network as part of the National Genome Research to T. M. S., D. W., and H. E. (grant numbers 01GS08164, 01GS08167, 01GS08163, “to T.B.H.”, by the Deutsche Forschungsgemeinschaft (SFB 665 C4) to G. S. and M. S.; by a Wellcome Trust Strategic Award (096919/Z/11/Z) and UK NHS Specialized “Rare Mitochondrial Disorders of Adults and Children” Service to R. W. T., a Wellcome Trust WT098051 to R. D.; and by the Novartis Foundation for Medical Research and the Vinetum Foundation to A. S.; C. L. A. is the recipient of a National Institute of Health Research (NIHR) doctoral fellowship (NIHR-HCS-D12-03-04). This study was supported in part by a grant from the Research Program of Innovative Cell Biology by Innovative Technology (Cell Innovation), a Grant-in-Aid for the Development of New Technology from The Promotion and Mutual Aid Corporation for Private Schools of Japan from MEXT (to Y. O.), Grants-in-Aid for the Research on Intractable Diseases (Mitochondrial Disease) from the Ministry of Health, Labour and Welfare (MHLW) of Japan to A. O. K. M. was supported by Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics.

Received: 29 January 2015; Accepted: 3 February 2015


doi: 10.1002/acn3.189

\*Contributing equally.

onset in the first year of life and course ranging from neonatal death to survival into adulthood. The most prominent clinical features were encephalopathy (10/10), deafness (9/9), epilepsy (6/9), optic atrophy (6/10), and cardiomyopathy (4/10). Serum lactate was elevated and brain magnetic resonance imaging showed white matter changes or a Leigh-like pattern resembling disorders of mitochondrial energy metabolism. Analysis of patients’ fibroblast cell lines (6/10) provided further evidence for the pathogenicity of the respective mutations by showing reduced ECHS1 protein levels and reduced 2-enoyl-CoA hydratase activity. While serum acylcarnitine profiles were largely normal, in vitro palmitate loading of patient fibroblasts revealed increased butyrylcarnitine, unmasking the functional defect in mitochondrial β-oxidation of short-chain fatty acids. Urinary excretion of 2-methyl-2,3-dihydroxybutyrate – a potential derivative of acryloyl-CoA in the valine catabolic pathway – was significantly increased, indicating impaired valine oxidation. Interpretation: In conclusion, we define the phenotypic spectrum of a new syndrome caused by ECHS1 deficiency. We speculate that both the β-oxidation defect and the block in l-valine metabolism, with accumulation of toxic methacryl-CoA and acryloyl-CoA, contribute to the disorder that may be amenable to metabolic treatment approaches.
**Introduction**

Short-chain enoyl-CoA hydratase (ECHS1, synonym: crotonase, EC 4.2.1.17), encoded by ECHS1 (cytogenetic location: 10q26.3; GenBank accession number: NM_004092.3; OMIM*602292), is a mitochondrial matrix enzyme that catalyzes the second step of the \( \beta \)-oxidation spiral of fatty acids, that is, the hydration of chain-shortened \( \alpha,\beta \)-unsaturated enoyl-CoA thioesters to produce \( \beta \)-hydroxyacyl-CoA.\(^1\) For each turn of this spiral pathway, one acetyl-CoA molecule is released and utilized for either the formation of citrate (tricarboxylic acid [TCA] cycle) or ketone bodies (ketogenesis). Decreased activity of mitochondrial \( \beta \)-oxidation of fatty acids thus decreases the formation of important energy substrates. Decreased formation of acetyl-CoA results in increased susceptibility to energy deficiency during catabolic states and to the dysfunction of organs that particularly rely on fatty acids and ketone bodies as their energy source (e.g., cardiac tissue). In addition, decreased formation of acetyl-CoA, and hence limited availability of acetate, hampers myelination because acetate is required for cholesterol biosynthesis. Moreover, decreased formation of acetyl-CoA may hamper posttranslational acetylation of mitochondrial proteins, a mechanism that is emerging as a critical regulator of mitochondrial function.\(^2\) Evidence is increasing that ECHS1 has a wide substrate specificity and thus also plays an important role in amino acid catabolism, in particular of valine, where it converts methacryl-CoA to (S)-3-hydroxyisobutyryl-CoA and acryloyl-CoA to 3-hydroxypropionyl-CoA (Fig. 1), the fourth step of valine oxidation.\(^3\) Accumulation of toxic methacryl-CoA and acryloyl-CoA, two highly reactive intermediates that spontaneously react with sulphydryl groups of, for example, cysteine and cysteamine, is suspected to cause brain pathology and biochemical phenotype in \( \beta \)-hydroxyisobutyryl-CoA hydrolase (HIBCH) deficiency, a disorder of the fifth step of valine oxidation with a Leigh-like phenotype and deficiency of multiple mitochondrial enzymes.\(^4,5\) Very recently, ECHS1 mutations were reported in two siblings with Leigh disease and remarkable clinical and biochemical similarities to HIBCH deficiency.\(^6\) Both presented soon after birth with generalized hypotonia, poor feeding, respiratory insufficiency, and developmental delay. They suffered a severe clinical course and died at the age of 4 and 8 months.

Here, we report 10 unrelated individuals, identified by exome sequencing, who carry compound heterozygous or homozygous ECHS1 mutations and present with a combination of (Leigh-like) mitochondrial encephalopathy, deafness, epilepsy, optic nerve atrophy, and cardiomyopathy. This work confirms ECHS1 mutations as a cause of mitochondrial disease, and defines the broad phenotypic spectrum of this new disorder which ranges from fatal neonatal courses to survival into adulthood.

**Patients and Methods**

Written informed consent was obtained from all patients investigated or their guardians and the ethics committee
of the Technische Universität München approved the study. The patients tested positive for ECHS1 mutations are part of a large cohort of cases with suspected mitochondrial disorders. DNA samples have been collected for genetic analyses in three different centers including Bern (Switzerland, 47 cases including family F2), Saitama (Japan, 180 cases including families F1 and F6), and Munich (Germany, 435 cases including families F3-5 and 7-10; Fig. 2). Clinical and biochemical findings of ECHS1 mutation-positive patients are summarized in Table 1 and representative abnormal magnetic resonance imaging (MRI) findings are shown in Figure 3. In addition, we report on four older siblings who have died undiagnosed with a clinical picture similar to the mitochondrial encephalomyopathy described in their younger siblings with a confirmed diagnosis of ECHS1 deficiency.

Regarding terminology, we avoided the term “Leigh syndrome” or “Leigh-like syndrome” for the whole group of our patients with ECHS1 deficiency, because these are ill-defined entities and many of our patients did not fulfill the criteria suggested by Rahman et al. In those individual cases that fulfilled the definition by Rahman, we preferred to use the more neutral term “Leigh-like syndrome” or “Leigh-like pattern in MRI.”

**Case reports**

Patient #346 (F1, II:2, c.[176A>G];[476A>G], p.[Asn59Ser];[Gln159Arg]), a girl, was born after a normal pregnancy at 39 weeks of gestation with normal birth measurements (weight 2935 g, length 50.5 cm) as the second child of unrelated Japanese and American parents. Soon after birth, she was admitted to a neonatal medical center for severe respiratory and cardiac failure with hypertrophic cardiomyopathy (HCM) and suspected deafness. There was profound lactic acidosis in blood (21–43 mmol/L, lower limit of normal 1.8 mmol/L), but metabolic profiling (amino acid analysis, urine organic acid analysis, acylcarnitine analysis) was unremarkable. Brain MRI at day 8 showed low intensity in cerebral white matter, and moderate brain atrophy at day 58. She died at the age of 4 months and autopsy was performed. Respiratory chain analysis showed mild deficiency of complex I in liver, but normal activities in muscle and heart. Her older sister died due to respiratory failure and severe lactic acidosis on her first day of life.

Patient #346 (F1, II:2, c.[176A>G];[476A>G], p.[Asn59Ser];[Gln159Arg]), a girl, was born after a normal pregnancy at 39 weeks of gestation with normal birth measurements. Postnatally, he developed lactic acidosis and neonatal seizures. Analysis of fibroblasts showed reduced pyruvate oxidation compatible with a complex I or pyruvate dehydrogenase defect, whereas enzymatic activities of the respiratory chain in muscle and fibroblasts were normal. These findings led to a therapeutic trial with ketogenic diet. The diet was stopped after a few months as no clinical response was observed. At 5 months of age, he had severely delayed motor development, hardly any head control, severe truncal hypotonia and intermittent episodes of opisthotonus. There was no reaction to visual or auditory stimuli. Despite gastric tube feeding, the child was severely underweight (−2.8 SD), of short stature (−3.4 SD), and microcephalic (−4.9 SD).

Laboratory investigation revealed persistently elevated lactate (2.4–6.0 mmol/L), mildly elevated CK and repeatedly normal acylcarnitines. Repeated electroencephalograms did not show epileptic discharges. Brain MRI at age 17 days showed normal myelinisation but symmetrical punctiform hyperintensities in the centrum semiovale. MR spectroscopy of basal ganglia showed elevated lactate. Ophthalmological examination suggested bilateral optic atrophy, and acoustic evoked potentials confirmed severe sensorineural deafness. At the age of 11 months, the child was found dead in his bed. Autopsy revealed morphological and histological findings of subacute necrotizing encephalopathy (Fig. 3E) and massive left ventricular hypertrophy.

Patient #68552 (F3, II:6, c.[476A>G];[476A>G], p.[Gln159Arg];[Gln159Arg]), a girl, is the sixth child of first cousins of Pakistani origin. Shortly after birth, the infant was found hypotonic with poor feeding and with high lactate (5.1 mmol/L). She was extremely irritable and had episodes of stiffness but electroencephalography (EEG) was normal. Even so, the baby was started on antiepileptic drug therapy as well as on baclofen. She was fed continuously by nasogastric tube. She showed no developmental progress nor developed any meaningful interaction with her environment and her irritability worsened episodically. Palliative care was instituted and she died aged 2 years and 4 months.

Brain MRI showed symmetrical white matter changes with a periventricular focus and extension into the subcortical areas of the frontal and parietal lobes. The thalami as well as the caudate and lentiform nuclei appeared normal. MR spectroscopy of basal ganglia showed no obvious lactate peak. Neonatal adrenoleukodystrophy, biotinidase deficiency, Krabbe disease, GM1 gangliosidosis and metachromatic leukodystrophy were excluded biochemically. There were no significant abnormalities of acylcarnitines, organic acids, glycosaminoglycans, oligosaccharides or amino acids (except a raised alanine in keeping with lactic acidosis). Invasive investigations such as muscle biopsy were refused.
**ECHS1** Mutations Cause Encephalocardiomyopathy

T. B. Haack et al.

Figure 2. Pedigrees of investigated families and short-chain enoyl-CoA hydratase (**ECHS1**) structure and conservation of identified mutations. (A) Pedigrees of 10 families with mutations in **ECHS1**. Mutation status of affected (closed symbols) and unaffected (open symbols) family members. (B) Gene structure of **ECHS1** with known protein domains of the gene product and localization and conservation of amino acid residues affected by mutations. Intronic regions are not drawn to scale.
<table>
<thead>
<tr>
<th>ID</th>
<th>Sex</th>
<th>ECHS1 mutations</th>
<th>Biochemical investigations</th>
<th>Clinical and biochemical features</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1, II:2 #346</td>
<td>F</td>
<td>c.[176A&gt;G]; [476A&gt;G]; p.[Asn59Ser]; [Gln159Arg]</td>
<td>RCCI-V&lt;sup&gt;2&lt;/sup&gt;</td>
<td>CI mildly ↓ Birth Died at age 4 m At age 8 d: white matter changes, brain atrophy (Fig. 3A), more prominent until age 58 d</td>
</tr>
<tr>
<td>F2, II:1 #42031</td>
<td>M</td>
<td>c.[197T&gt;C]; [449A&gt;G]; p.[Ile66Thr]; [Asp150Gly]</td>
<td>RCCI-V&lt;sup&gt;1&lt;/sup&gt; PDHc&lt;sup&gt;1&lt;/sup&gt; Substrate oxidation&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Normal Normal Birth Died at age 11 m At age 17 d: normal myelinisation, symmetrical punctiform hyperintensities in centrum semiovale MRS: lactate ↑</td>
</tr>
<tr>
<td>F3, II:6 #68552</td>
<td>F</td>
<td>c.[476A&gt;G]; [476A&gt;G]; p.[Gln159Arg]; [Gln159Arg]</td>
<td>n.d. n.d.</td>
<td>Birth Died at age 2.3 y Symmetrical white matter changes</td>
</tr>
<tr>
<td>F4, II:1 #68761</td>
<td>M</td>
<td>c.[161G&gt;A(;)]; 817A&gt;G; p.[Arg54His(); Lys273Glu]</td>
<td>RCCI-V ATP production</td>
<td>Normal Decreased Birth Died at age 7.5 y At age 4 y: extensive brain atrophy MRS: normal lactate</td>
</tr>
<tr>
<td>F5, II:3 #73663</td>
<td>F</td>
<td>c.[673T&gt;C]; [673T&gt;C]; p.[Cys225Arg]; [Cys225Arg]</td>
<td>RCCI-V PDHc Substrate oxidation</td>
<td>Normal Normal Birth Alive at age 2 y Delayed myelination, T&lt;sub&gt;2&lt;/sub&gt;-hyperintense periphery white matter lesions, liquorisointense lesions in</td>
</tr>
</tbody>
</table>

Continued...
Table 1. Continued.

<table>
<thead>
<tr>
<th>ID</th>
<th>Sex</th>
<th>ECHS1 mutations</th>
<th>cDNA (NM_004092.3)</th>
<th>protein (NP_004083.3)</th>
<th>Biochemical investigations</th>
<th>Clinical and biochemical features</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Neuroimaging (MRI, MRS)</td>
<td>Hearing loss</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>F6, II:1</strong></td>
<td>F</td>
<td>c.[98T&gt;C]; [176A&gt;G]; p.[Phe33Ser]; [Asn159Ser]</td>
<td>RC CHV</td>
<td>CIV mildly↓</td>
<td>Birth</td>
<td>Alive at age 3 y</td>
</tr>
<tr>
<td>#376</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>F7, II:2</strong></td>
<td>F</td>
<td>c.[268G&gt;A]; [583G&gt;A]; p.[Gly90Arg]; [Gly195Ser]</td>
<td>RC CHV¹; PDH¹</td>
<td>Normal</td>
<td>Normal</td>
<td>2 y</td>
</tr>
<tr>
<td>#76556</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>F8, II:1</strong></td>
<td>F</td>
<td>c.[161G&gt;A]; [91G&gt;A]; p.[Arg54His]; [Ala132Thr]</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
<td>1 y</td>
</tr>
<tr>
<td>#MRB166</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>F9, II:2</strong></td>
<td>F</td>
<td>c.[161G&gt;A]; [43dup]; p.[Arg54His]; [Lys145Alafs*6]</td>
<td>RC CHV; Pyruvate oxidation</td>
<td>Normal</td>
<td>Normal</td>
<td>Birth</td>
</tr>
<tr>
<td>#37277</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
Molecular genetic screening demonstrated a maternally transmitted m.1555A>G MTNR1 mtDNA mutation that is characteristically associated with aminoglycoside-induced hearing loss. This was not felt to be responsible for the patient’s condition.

Three older siblings of this patient had congenital lactic acidosis and died between the ages of 1 and 2 years. The first two affected children were identical twin girls and the third affected child was a boy. The history is identical in all three children. They were all born at term via normal vaginal delivery. There was no history of birth asphyxia and they were apparently well soon after birth. They fed well initially but became symptomatic aged between 1 and 2 days with generalized tonic-clonic seizures. Subsequently, they had poor feeding and severe developmental delay. The seizures were recurrent but well controlled with anticonvulsants. They were tube-fed from the first few days of life as they were unable to suck and swallow effectively. They had severe developmental delay from the outset and showed little evidence of development during infancy. They always had a poor head control, poor eye contact, and a poor smile. They were never able to reach out and their hearing was possibly impaired. There was no history of dystonia and they were said to be very hypertonic. There were no breathing problems reported. They apparently had no renal tubular acidosis but they required some treatment with bicarbonate for metabolic acidosis (lactate levels of ~5.0 mmol/L). There was no history of cardiac or liver involvement. The twin girls died aged 2 years and the boy died aged 1 year. In the twin girls, a diagnosis of complex I deficiency was established on muscle biopsy respiratory chain enzyme analysis. Testing of ECHS1 performed on newborn screening bloodspots of the twin older siblings (F3, II:1 and II:2) confirmed that they were also homozygous for the c.476A>G, p.Gln159Arg variant. The children were treated with sodium bicarbonate, anticonvulsants, and a mitochondrial vitamin cocktail as well as nasogastric tube feeding. The family has two other healthy girls, now teenagers.

Patient #68761 (F4, II:1, c.[161G>A];[817A>G] p.[Arg54His;Lys273Glu]), a boy, is the first child to healthy unrelated parents from The Netherlands. After a normal pregnancy, he was born at gestational age 39 + 1 weeks by Cesarean section on maternal indication with a birth weight of 3990 g. Apgar scores were 8 after 1 min and 9 after 5 min. Mild generalized muscular hypotonia was observed upon birth which was accompanied by feeding problems until the age of 5 months. Thereafter, his clinical condition declined and he developed severe encephalopathy with hardly any spontaneous movements of the head and trunk, swallowing problems, and episodes of inconsolable crying. He depended on

<table>
<thead>
<tr>
<th>Table 1. Continued.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ID</td>
</tr>
<tr>
<td>-----</td>
</tr>
<tr>
<td>F10, II:1</td>
</tr>
<tr>
<td>#52236</td>
</tr>
</tbody>
</table>

ECHS1, short-chain enoyl-CoA hydratase; MRI, magnetic resonance imaging; AO, age of onset; m, months; y, years; n.a. not applicable; HCM, hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy; RCC, respiratory chain complexes (RCC) in muscle; I, NADH:CoQ oxidoreductase; II, succinate dehydrogenase; II + III, succinate:cytochrome c reductase; IV, cytochrome c oxidase (COX). Enzyme activities were determined in muscle biopsies if not stated otherwise (investigated in fibroblast cell lines, investigated in liver) and normalized to citrate synthase (CS).
tube feeding and suffered from epilepsy with hypsarrhythmia and multifocal epileptic activity in the EEG at the age of 1 and 3 years.

On physical examination, he was unable to make contact or follow objects, showed virtually no spontaneous movements, but only dystonic movements of arms and legs. Over the course of the disease axial hypotonia and hypertonia of the limbs persisted, dystonic movements diminished, and he did not make any developmental progress. Laboratory tests showed chronic iron deficiency leading to anemia. Physical examination at the age of 6 years showed microcephaly, scoliosis, and muscular hypotonia. The child died at the age of 7.5 years due to respiratory insufficiency in the course of a pulmonary infection.

Brain MRI at the age of 1 year showed atrophy of caudate nuclei, corpus callosum, mesencephalon, and pons. These changes were progressive at age 4 years showing extensive white and gray matter brain atrophy, mainly in frontal and temporal lobes bilaterally with subsequent widening of the subarachnoid space and of ventricular system. Brain MR spectroscopy showed an overall decrease in NAA being most pronounced in the basal ganglia but no elevation of lactate.

Cardiac ultrasound at the ages of 1 and 4 years showed no structural or functional abnormalities. Biochemical analysis of a skeletal muscle specimen showed normal citrate synthase (CS)-adjusted activities of respiratory chain complexes I–V but a decreased overall ATP production. Pathogenic mutations of the mitochondrial DNA were excluded by Sanger sequencing of DNA from muscle.

Patient #73663 (F5, II:3, c.[673T>C];[673T>C], p.[Cys225Arg];[Cys225Arg]), a girl, was born at term as the third child of consanguineous parents after normal pregnancy and spontaneous vaginal delivery. On day 5, she was admitted to hospital due to rapid loss of body weight (24% below birth weight) and severe metabolic acidosis (pH 6.86). Lactate, alanine, and ketone bodies were also strongly increased leading to the suspicion of an inherited disorder of mitochondrial energy metabolism. Following this neonatal decompensation she showed a severe global developmental delay, severe generalized spastic tetraparesis, myoclonic epilepsy, and HCM. At age 16 months, she had a cardiac arrest following a diagnostic muscle and skin biopsy. She survived after 45 min of cardiopulmonary resuscitation but several complications followed this event (ARDS, sepsis, aspiration pneumonia, acute renal failure, and acute hepatic failure). At age 2.3 years she does not show active movement of arms and legs and is not able to sit, stand or walk. She neither speaks nor fixes or follows persons and objects. She reacts to voices and noise.

Cranial MRI performed at age 13 months showed delayed myelination, a thin corpus callosum, and T2 signal abnormalities in the periventricular white matter. Lesions in putamen and globus pallidus were also found. MR spectroscopy of gray and white matter was normal. Metabolic work-up revealed elevated serum lactate (up to 8.5 mmol/L), moderately elevated plasma alanine (up to 630 μmol/L), slightly elevated ethylmalonic acid in urine (60 mmol/mol creatinine), and intermittently low plasma ketone bodies in preprandial state. Hyperuricemia was found. Acylcarnitine profiling was normal. Radiometric and single enzyme analysis of OXPHOS in frozen muscle tissue did not confirm the suspected diagnosis of a mitochondrial disorder.

A brother of this girl has died at age 4 months during an acute decompensation similar to that described above. He also had severe developmental delay, elevated lactate and metabolic acidosis. Similar to his younger sister, liver,
skin, and muscle biopsy did not confirm a respiratory chain defect in this child.

Patient #376 (F6, II:1, c.[98T>C];[176A>G], p.[Phe33Ser];[Asn59Ser]), a girl, was born after an uneventful pregnancy at 39 weeks of gestation with normal birth measurements (weight 3124 g, length 51 cm) as the first child of unrelated Japanese parents. At the age of 2 days, she had epileptic seizures and was treated with phenobarbital. In her first months, developmental delay and muscular hypotonia were noted. At the age of 8 months, she developed respiratory failure and unconsciousness, and was admitted to hospital. Transient lactic acidosis in blood (8.0 mmol/L, lower limit of normal 1.8 mmol/L) was found. Metabolic profiling (amino acid analysis, urine organic acid analysis, and acylcarnitine analysis) was unremarkable. Brain CT and MRI at 8 months showed symmetrical, bilateral signal abnormalities in basal ganglia, and she was diagnosed with Leigh-like syndrome. At the age of 1 year, she developed deafness, and at the age of 3 years dilated cardiomyopathy. Muscle biopsy showed mild deficiency of complex IV.

Patient #76656 (F7, II:2, c.[268G>A];[583G>A], p.[Gly90Arg];[Gly195Ser]), a girl, is the child of healthy unrelated German parents. After a normal pregnancy, she was born at term with normal birth measurements. The early motor development was normal, and she started walking at the age of 14 months. The girl was referred at age 2 years because of stiffness of gait and a tendency to fall. At admission, she showed muscular hypotonia, coordination problems, choreoathetotic movements, delayed speech development, and sensorineural deafness, which had been treated with hearing aids. Blood chemistry was normal including lactate, amino acids and organic acids.

Brain MRI at age 2 years showed no cerebral, cerebellar, or callosal atrophy but mild bilateral signal hyperintensities of putamen, globus pallidus, nucleus caudatus, and periventricular white matter. MR spectroscopy of basal ganglia showed mild elevation of lactate.

A muscle biopsy showed only unspecific morphologic findings, and biochemical analysis of respiratory chain activities was unremarkable.

Patient #MRB166 (F8, II:1, c.[161G>A];[394G>A], p.[Arg54His];[Ala132Thr]), a girl, is the first child of healthy unrelated German parents. Pregnancy was complicated by oligohydramnion and a diagnosis of gastrochisis. She was born by Cesarean section at 34 weeks of gestation with normal birth measurements (weight 1490 g [3rd percentile], length 41 cm [25th percentile], and head circumference 31 cm [25th percentile]). Surgical correction of gastrochisis was performed. The girl needed phototherapy for icterus neonatorum, tube feeding, and assisted ventilation. Deafness was diagnosed with 2 years of age and treated by cochlear implants. One seizure was observed at the age of 7 years. She showed truncal hypotonia, gait ataxia, and severe developmental delay (crawling at 1.5 years, sitting at 3 years, assisted walking at 5 years of age and no speech at 8 years). She has an oval face, a broad nasal tip, a large mouth, a high arched palate, and a receding chin. MLPA PWS/AS, UBE3A, and MECP2 mutation analysis and microarray gave normal results.

Patient #57277 (F9, II:2, c.[161G>A];[431dup], p.[Arg54His];[Leu145Alafs*6]), a girl, is the second child of healthy nonconsanguineous parents from Germany. She was born after a normal pregnancy at 41 weeks of gestation with normal body measurements. Early motor development was delayed, and she never acquired the ability to sit or walk independently. Acquisition of language was impeded by sensorineural deafness for which she was fitted with hearing aids. At 18 months parents noted a pendular nystagmus with a rotatory component as well as loss of central vision due to optic atrophy. Residual vision at 10 years was 0.3. From 2 years of age her motor abilities deteriorated during episodes of febrile illness and lactic acidemia when she developed a movement disorder that undulated between dystonia (opisthotonus) and chorea. Treatment with Levodopa/Carbidopa worsened her symptoms. She is presently 16 years old. Her body length is at and her weight 1 kg below the third percentile. Due to dysphagia and her inability to chew she has to be fed minced food. Massive caries and enamel defects from trismus required general dental repair and reconstruction under anesthesia. She visits a secondary school for disabled children, and communicates through a voice computer by saying “yes” or “no” or by making hand gestures.

Cranial MRI at the age of 1.5 years showed Leigh-like lesions with increased T2-signal intensity in the putamen and globus pallidus which became more prominent until age 2.2 years (Fig. 3C). Proton spectroscopy in the basal ganglia showed an increased lactate peak. Laboratory examinations revealed mildly increased urine excretion of lactate and lactic acidemia (2.5–4.0 mmol/L). The amino acid profile was normal in cerebrospinal fluid (CSF) and plasma. CPK was normal and muscle biopsy at 2 years of age only showed unspecific myopathic changes. Biochemical investigation revealed normal activities for the OXPHOS complexes, CS, PDHc as well as in vitro pyruvate oxidation.

Patient #52236 (F10, II:1, c.[229G>C];[476A>G], p.[Glu77Gln];[Gln159Arg]), a girl, is the first child of healthy unrelated German parents. After a normal pregnancy, she was born at 42 weeks of gestation with normal birth measurements (weight 3120 g, length 51 cm). Motor development was considered normal during the first months of life, and she started walking at the age of
ECHS1 Mutations Cause Encephalocardiomyopathy

T. B. Haack et al.

11 months. From this age, however, short episodes of fist clenching, teeth gnashing, horizontal nystagmus and unresponsiveness were noted. Although repeated EEG did not show epileptic discharges, treatment with phenytoin was started and maintained until age 5 years when the attacks disappeared. From age 17 months, progressive gait abnormalities were observed. These were episodic in the beginning, but evolved into a paraspastic gait in early childhood, and the girl became wheelchair-dependent at age 9.5 years. From age 2 years, visual problems became evident, and examination showed bilateral optic atrophy. Visual acuity at age 13 years was 1/50 for both eyes. From age 7 years, progressive sensorineural deafness was found, and the patient was supplied with hearing aids at age 9.5 years. At the same age, mild mental retardation and dysarthria were noted. The patient completed a secondary school for blind children, and has been working in a workplace for disabled persons from age 18 years.

Examination at age 31 years showed short stature (155 cm) and low body weight (40 kg). Visual acuity was off-chart, the patient could only notice hand movements, and there was a pendular nystagmus of the blind. Communication was impeded by severe dysarthria. She had generalized dystonia and a spastic tetraparesis, leading to an inability to walk independently. Sensation was entirely normal.

Electromyography (EMG), neurography and repeated EEG were normal. Laboratory examinations showed mildly elevated lactate (2.5 mmol/L, normal <1.8 mmol/L) in CSF and inconsistently in serum (2.0–2.8 mmol/L, normal <2.2 mmol/L). A muscle biopsy at age 9 years showed some type II fiber atrophy due to immobilization and a faint accumulation of lipid droplets in single fibers. There were no ragged red fibers (RRF) and no cytochrome c oxidase (COX) deficiency, and biochemical analysis of respiratory chain activities showed normal results. Brain MRI at age 15 years showed exclusively Leigh-like signal hyperintensities in the caput nuclei caudati and putamen bilaterally (Fig. 3D). MR spectroscopy of the left putamen showed no elevation of lactate.

Genetic analysis

We used a dual approach of exome sequencing and panel sequencing to analyze a cohort of patients with suspected mitochondrial disorders. Seven index patients (#52236, #57277, #68552, #68761, #73663, #76656, and #MRB166) were investigated by exome sequencing in Germany as described previously. In brief, we used a SureSelect Human All Exon 50 Mb Kit (Agilent) for enrichment and a HiSeq2500 (Illumina) for sequencing. Reads were aligned to the human reference assembly (hg19) with BWA (version 0.5.8 Open source software, Wellcome Trust Sanger Institute). More than 90% of the exome was covered at least 20× allowing for high-confidence variant calls. Single-nucleotide variants (SNVs) and small insertions and deletions were detected with SAMtools (version 0.1.7 Open source software, Wellcome Trust Sanger Institute). Variant prioritization was performed based on the autosomal-recessive patterns of inheritance and the notion that the clinical mitochondrial phenotype of the patients is very rare. We therefore excluded variants with a frequency higher than 0.1% in 3850 control exomes and public databases and focused on genes encoding mitochondrial proteins carrying two potentially pathogenic DNA variants. In two other patients (#346 and #376) we used a TruSeq Exome kit from Illumina. A detailed description of the bioinformatic pipeline and variant filtering used for these two cases has been published recently.

In patient #42031 we applied targeted enrichment of 1476 nuclear genes (including 1013 genes coding for mitochondrial proteins according to the MitoCarta) using an in-solution hybridization capture method ( NimbleGen Madison, WI, USA). Paired-end sequencing was performed on a HiSeq2500 (Illumina) to an average 178× coverage. Sequence alignment and variant calling was done with CLC Workbench v.7.0.4. CLC bio, Aarhus, Denmark.

We used Sanger sequencing to confirm all identified ECHS1 mutations and to test the carrier status of available family members. Primer sequences and PCR conditions are available upon request.

Western blotting

Immunoblotting was performed using two different protocols. For the analysis of F2;II:1 (#42031), F10, II:2 (#52236), F9,II:2 (#57277), F5, II:3 (#73663) 45 μg of protein of patients’ fibroblast cell homogenates were separated on 13% sodiumdodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) along with a protein standard (Precision Plus Protein Kaleidoscope, Biorad Hercules, CA, USA) and blotted onto polyvinylidene fluoride membranes (Immobilon, Merck Millipore Darmstadt, Germany). Primary antibodies were as follows: ECHS1 (66117, Proteintech Chicago, IL, USA), β-actin (ab13822, Abcam Cambridge, UK). Chemiluminescence detection was performed on an Odyssey Biomedical: Phoenix, AZ, USA infrared imaging system according to the manufacturer’s instructions. For the analysis of F1, II:2 (#346), and F6, II:1 (#376) mitochondria were isolated by homogenization of cells in mitochondrial isolation buffer (20 mmol/L HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid pH 7.4, 220 mmol/L mannitol, 70 mmol/L sucrose, 1 mmol/L Ethylenediaminetetraacetic acid) with
2 mg/mL Bovine serum albumin. Cell homogenates were centrifuged at 700g at 4°C for 5 min and postnuclear supernatant was collected. Mitochondria were pelleted by centrifugation at 10,000g at 4°C for 5 min and mitochondrial pellet was resuspended in mitochondrial isolation buffer for subsequent size-separation on 10% gels by SDS-PAGE, and transfer to a methanol-activated PVDF membrane. Immunoblotting was performed with primary antibodies from GeneTex (ECHS1) and Abcam (HSP60). Chemiluminescence detection was achieved with ECL Select (GE Healthcare, Little Chalfont, UK) and the membrane was viewed with the LAS4000 (GE Healthcare, Little Chalfont, UK), according to the manufacturer’s instructions.

Analysis of 2-enoyl-CoA hydratase activity

2-enoyl-CoA hydratase (ECHS1) activity was measured spectrophotometrically in fibroblast cell lysates following the absorbance of the unsaturated substrate crotonyl-CoA over time (15 min) as described. Briefly, trypsinized fibroblasts were resuspended in reduced Triton-X-100 at 37°C and lysed by sonication. Lysates were centrifuged at 700g for 5 min to remove cellular debris and protein concentrations were determined in supernatants by the BCA method. The reaction mixture consisted of: 100 mmol/L potassium phosphate buffer (pH 8) for a final concentration of 0.1 mg/mL BSA and 50 μL of cell homogenate for a total of 15 μg of protein. The reaction was started with 50 μL of 250 μmol/L crotonyl-CoA for a final concentration of 25 μmol/L. Samples were measured at 37°C in UV cuvettes at 263 nm in a Shimadzu spectrophotometer. Enzymatic activity was calculated using a molar extinction coefficient of 6700. Enzymatic activity was normalized to the mitochondrial marker enzyme CS as previously described. All reactions were performed in at least three independent experiments in triplicates with similar findings.

Palmitate loading assay

Palmitate loading in human skin fibroblasts of ECHS1 patients, healthy volunteers as negative controls and fibroblasts of patients with short- and medium-chain acyl-CoA dehydrogenase (MCAD) deficiency as disease controls were performed as previously described. In brief, cell cultures were maintained in Dulbecco’s modified Eagle medium (Invitrogen, Darmstadt, Germany) supplemented with 2 mmol/L glutamine, 10% fetal calf serum, 1% penicillin/streptomycin, and Fungizone™ (all from Invitrogen) at 37°C and 5% CO2 in a humidified atmosphere until confluency. Palmitate loading was performed in serum- and glutamine-free minimal essential medium (Invitrogen) containing palmitic acid (200 μmol/L; Sigma-Aldrich Taufkirchen, Germany), L-carnitine (400 μmol/L; Sigma), and bovine serum albumin (0.4%; fatty acid-free; Sigma). After the end of the 96 h-incubation period, 10 μL aliquots of the cell culture media were collected and mixed with isotope-labeled internal standard (Cambridge Isotope Laboratories, Tewksbury, MA 01876) in methanol. Twenty-five microliters of the butylated sample were used to analyze the acylcarnitine profile by tandem mass spectrometry. For each sample at least two independent measurements were performed. The acylcarnitine concentration was normalized to the protein content of the fibroblast sample and expressed as nmol/mg protein.

For the analysis of palmitate-dependent mitochondrial respiration, control and patient fibroblasts were seeded at a density of 20,000 cells/well in 80 μL of high glucose Dulbecco’s modified media (Gibco:Life Technologies, Darmstadt, Germany) supplemented with 10% fetal bovine serum (Invitrogen), 1% penicillin-streptomycin (Invitrogen) and 200 μmol/L uridine (Sigma) in a XF 96-well cell culture microplate (Seahorse Bioscience, North Billerica, MA, USA) and incubated overnight at 37°C in 5% CO2. Culture medium was replaced with 160 μL of serum- and glutamine-free minimal essential medium (Invitrogen) supplemented with L-carnitine (400 μmol/L; Sigma), and bovine serum albumin (0.4%; fatty acid-free; Sigma) and cells were incubated for 24 h at 37°C in 5% CO2. Palmitate-BSA complex was prepared according to the manufacturer’s protocol (Seahorse Bioscience). Oxygen consumption rate (OCR) was measured using a XF16 Extracellular Flux Analyzer 2 (Seahorse Biosciences). OCR was determined with no additions; after addition of BSA (30 μmol/L) or palmitate-BSA conjugate (180/30 μmol/L).

Results

Exome sequencing identifies ECHS1 mutations

We applied whole exome sequencing in a cohort of 435 individuals with a suspected disorder of mitochondrial energy metabolism and identified six unrelated affected individuals carrying two heterozygous or homozygous rare variants (minor allele frequency [MAF] <0.1%) in ECHS1 (Fig. 2). Applying the same variant selection criteria to our in-house exome datasets from 3850 patients referred with presumed nonmitochondrial phenotypes revealed rare recessive-type ECHS1 variants in one additional index case, F8, II.1 (#MRB166, Fig. 2). This patient was investigated in the context of an intellectual disability study but the relevance of the ECHS1 variants was hitherto unclear. Clinical follow-up and review of medical reports revealed, however, that the neurologic features of this patient
(deafness, seizures, hypotonia, ataxia, and developmental delay) are very well compatible with a mitochondrial disorder. In contrast, it remains unclear whether the dysmorphic signs in this patient are related to the ECHS1 deficiency as dysmorphism is rather uncommon in mitochondrial diseases and was not found in any of the other ECHS1-deficient patients. The enrichment of rare biallelic ECHS1 variants in genomes of individuals with a suspected mitochondrial disorder (n = 7) compared to 3850 control genomes was genome-wide significant (P < 1.1 × 10^{-7}, Fisher exact test). In addition, in several individuals, ECHS1 was the only gene coding for proteins with a predicted or confirmed mitochondrial localization harboring two rare DNA variants. We gained further evidence for a disease association of ECHS1 by exome sequencing of 180 Japanese individuals with suspected mitochondrial disorders which identified two additional ECHS1-mutant individuals, F1, II.2 (#346) and F6, II.1 (#376, Fig. 2). By panel sequencing in a further patient with a similar clinical presentation we identified two heterozygous ECHS1 mutations in F2, II:1 (#42031, Fig. 2). The combined approaches of exome and candidate gene sequencing identified a total of 13 different disease alleles in ten index patients. Pedigrees of investigated families and localization of identified ECHS1 mutations as well as the evolutionary conservation of affected amino acid residues are shown in Figure 2B. All ECHS1 mutations were confirmed by Sanger sequencing in the index patients. Carrier testing of available parental samples confirmed a biallelic localization of the mutations. DNA from the parents was not available in families F4 and F6, however, in the latter a compound heterozygous state of the mutations was confirmed by haplotype phasing. The healthy siblings of families F10, F9, F3, and F7 were either wild-types or heterozygous carriers. For families F3, F5, and F1, family history was positive for the occurrence of similar clinical conditions but no DNA samples were available for molecular tests from individuals F1, II:1 and F3, II:3.

Of the 13 different ECHS1 mutations identified in our cohort, only one, c.431dup, p.Leu145Alafs*, predicts a premature truncation and loss of function of the protein (Table S1). All other detected mutations are missense variants, indicating that a complete loss of ECHS1 function may be embryonic lethal. With the exception of the c.268G>A, p.Gly90Arg variant, all are predicted to be disease-causing (MutationTaster2).16 Although all variants are rare (MAF < 0.05%), three mutations were identified in more than one family (c.161G>A, p.Asp54His, n = 3; c.176A>G, p.Asn59Ser, n = 2; and c.476A>G, p.Gln159Arg, n = 2), in each case with different mutations on the other allele. In addition, the c.476A>G, p.Gln159Arg mutation was found in the homozygous state in a third, consanguineous family. However, there is no mutational hotspot and the identified mutations are distributed across all eight coding exons of ECHS1 except for exons 1 and 7 (Fig. 2B).

**Functional consequences of ECHS1 mutations**

Next, we analyzed the consequences of ECHS1 mutations in fibroblast cell lines. In six cell lines, we investigated ECHS1 protein levels and in four of them we measured 2-enoyl-CoA hydratase activity. SDS-PAGE separation of mitochondrial fractions and total cell lysates followed by immunodetection with an antibody against ECHS1 revealed a severe decrease in ECHS1 steady-state levels in all patient-derived fibroblast cell lines. To test the functional impact of ECHS1 mutations, we determined 2-enoyl-CoA hydratase activity in the fibroblasts cell lysates from individuals F2, II.1 (#42031), F10, II.2 (#52236), F9, II.2 (#57277), and F5, II.3 (#73663). The 2-enoyl-CoA hydratase activity was markedly reduced in patients’ cell lines with residual activities varying between 14% and 50% of controls (Fig. 3B).

Palmitate loading in fibroblasts of three ECHS1 patients induced an acylcarnitine profile very similar to that of short-chain acyl-CoA dehydrogenase (SCAD) deficiency. The characteristic metabolite, butyrylcarnitine, increased to 170%, 199%, or 273% of the upper normal range of the controls. In another ECHS1-deficient patient, however, butyrylcarnitine was within the range of controls (48% of the upper normal range). In comparison, butyrylcarnitine increased to 388% of controls in patient fibroblasts with SCAD deficiency and 44% in MCAD deficiency. These results indicate that ECHS1 deficiency results in a mild functional disorder of short-chain fatty acid oxidation.

This notion is further supported by the observation of reduced palmitate-dependent respiration in patient-derived fibroblasts compared to controls (Fig. 4C). Noteworthy, in the three cell lines tested for both 2-enoyl-CoA hydratase activity and palmitate-dependent respiration, the severity of defects correlated. Together, these data provide evidence for the pathogenicity of eleven ECHS1 alleles.

**Organic acids in urine**

In analogy, organic acid analysis by gas chromatography/mass spectrometry in urine of patient #73663 revealed slightly elevated concentrations of ethylmalonate, a key metabolite of SCAD deficiency. Functional deficiency of short-chain fatty acid oxidation was also shown by intermittently elevated plasma fatty acids (250–780 μmol/L; normal <300 μmol/L) with concomitantly low normal
plasma ketone bodies (65–90 μmol/L; normal <200 μmol/L) in postprandial state of some patients. However, ketogenesis was only mildly impaired which was shown by a mild increase in ketone bodies during catabolism (570–630 μmol/L, normal <3000 μmol/L). In addition, we identified 2-methyl-2,3-dihydroxybutyrate which likely derives from acryloyl-CoA or, alternatively, methacrylyl-CoA, both metabolites of valine oxidation, in urines of four ECHS1 patients. This metabolite correlated with disease severity as its concentration was 229-fold higher than the median value in 35 controls in the severely affected patient #42031 (onset at birth, died at 11 months), 39-fold higher in patient #73663 (onset on day 5, alive at 2 years), sixfold higher in patient #76656 (onset at 2 years, alive at 5 years), and even in the normal range in the mildest affected case #52236 (onset at 11 months, alive at 31 years), the only patient who survived into adulthood.

**Phenotypic features of ECHS1 deficiency**

In contrast to gene identification strategies in which an a priori phenotypic stratification of the investigated cohort was the main key to success, this group of ECHS1-mutant individuals was identified by exome sequencing of a large cohort of individuals with suspected mitochondrial disorders. This approach allows for a rather unbiased assessment of the phenotypic spectrum associated with ECHS1 deficiency.

Disease severity ranged from presentations with neonatal onset and death in early infancy to survival into adulthood. In nine of 10 affected individuals, pregnancy was
normal and the children were born at term with normal body measurements. First clinical signs appeared in the prenatal period in one individual (oligohydramnios) and in the neonatal period (first month) in seven. Presenting signs included epileptic seizures, muscular hypotonia, respiratory and cardiac failure, failure to thrive, elevated lactate, and metabolic acidosis. In the two mildest affected individuals, developmental delay (F9, II:2, #57277) or episodic neurological symptoms (F10, II:1, #52236) were noted in the first year of life and lactate elevations were only intermittent and mild. While six of 10 affected individuals are still alive at the age of 2, 3, 5, 8, 16, and 31 years, four died at the age of 4, 11, 28, and 90 months, respectively. Interestingly, cardiomyopathy was only found in the individuals with a severe course and early death and none of the patients over 3 years of age.

In the course of the disease, neurological signs are most prominent including sensorineural deafness (9/9), developmental delay (8/10), epileptic seizures (6/9), dystonia (5/9), optic atrophy (6/10), muscular hypotonia (6/10), and spastic paresis (2/10). Other clinical features include cardiomyopathy (4/10) and respiratory failure (3/10). Increased blood, urine, and CSF lactate levels were found in seven of 10 individuals. Brain MRI was performed in nine of 10 individuals and showed white matter changes and brain atrophy in the very severe, early onset cases (n = 5) and Leigh-like bilateral T2 hyperintensities in the basal ganglia (nucleus caudatus, putamen, and globus pallidus) in the less severely affected individuals (n = 4; Fig. 3). MR spectroscopy of basal ganglia showed elevated lactate concentrations in three of seven individuals.

Taken together, our findings identified ECHS1 mutations as a cause of a new clinical entity characterized by an early onset, very severe (Leigh-like) mitochondrial encephalopathy with deafness, epilepsy, optic atrophy, and cardiomyopathy. Consistently elevated plasma concentrations of lactate indicate a dysfunction of the mitochondrial energy metabolism.

In view of the triad of (1) a severe progressive encephalopathy, (2) associated with bilateral basal ganglia lesions in MRI and autopsy, and (3) the mitochondrial dysfunction, ECHS1 deficiency is a new Leigh-like syndrome but can be differentiated from other forms of Leigh syndrome clinically and biochemically.

Analysis of OXPHOS enzymes in muscle tissue and fibroblasts

Since the clinical presentation suggested a mitochondrial disorder, eight of 10 patients received muscle and/or skin biopsies with detailed analysis of respiratory chain complexes, pyruvate dehydrogenase complex, ATP production, and pyruvate oxidation. Despite the severe clinical presentation of ECHS1 patients, only four of them showed mild and inconsistent changes in pyruvate oxidation (patient #42031), ATP production (patient #68761), and decreased activities of NADH:CoQ oxidoreductase (complex I of the respiratory chain) or cytochrome c oxidase (complex IV of the respiratory chain). Noteworthy, all these patients died (age of death: 4 months, 11 months, 3 years, 7.5 years), whereas four patients without documented changes in these analyses (#52236, #57277, #73663, #76656) have survived until now (age at latest visit: 2, 5, 16, and 31 years of life).

Discussion

ECHS1 is a mitochondrial matrix enzyme that is involved in several metabolic pathways including fatty acids and amino acids. Deficiency of this enzyme is expected to result in impaired mitochondrial fatty acid oxidation. However, as the membrane-bound enzymatic machinery of long-chain fatty acids remains intact, ketogenesis should not be completely disrupted in ECHS1-deficient individuals and, assumingly, the resulting clinical phenotype should be relatively benign – similar to SCAD deficiency. In fact, ECHS1-deficient individuals showed mild to moderate hypoketosis, but did neither present with hypoketotic hypoglycemia and hypoglycemic encephalopathy nor were acylcarnitine profiles in blood suggestive of a mitochondrial β-oxidation disorder. Deficiency of short-chain fatty acid oxidation, however, was unmasked by palmitate loading of ECHS1-deficient fibroblasts (Fig. 4C). This metabolic challenge induced a selective increase in butyrylcarnitine in three of four patients tested, which in combination with slightly increased ethylmalonate in urine reflects impaired oxidation of short-chain fatty acids.

Despite this relatively mild metabolic derangement (concerning mitochondrial β-oxidation), ECHS1-deficient individuals presented with a severe clinical phenotype, with a high frequency of Leigh-like syndrome, neonatal lactic acidosis, sensorineural hearing loss, muscular hypotonia, cardiomyopathy, and respiratory failure. Although this combination of clinical findings, in particular the leading neurological presentation, is rather uncommon for fatty oxidation defects, there is some clinical overlap with long-chain acyl-CoA dehydrogenase (LCHAD) deficiency and mitochondrial trifunctional protein (MTP) deficiency which resemble a primary OXPHOS deficiency. Affected individuals with LCHAD and MTP deficiency show a high frequency of neurological signs and symptoms including developmental delay, muscular hypotonia, epilepsy, and lipid storage myopathy as well as cardiomyopathy and sudden death in newborns and infants. Similar to ECHS1 deficiency, elevated lactate is also often
found in LCHAD/MTP deficiency suggesting mitochondrial dysfunction. In contrast to ECHS1 deficiency, however, individuals with LCHAD/MTP deficiency often present with hepatic dysfunction, retinopathy and peripheral neuropathy, but usually lack dystonia and sensorineural hearing loss. Interestingly, accumulating long-chain fatty acids and acyl-CoA are thought to act as mitochondrial toxins inhibiting energy metabolism in individuals with LCHAD and MTP deficiency.

The striking discrepancy between an expected moderate impairment of mitochondrial fatty acid oxidation and the severe clinical presentation of ECHS1-deficient individuals argues for an additional pathomechanism. In addition to its function in fatty acid oxidation, ECHS1 has also been suggested to be involved in the L-isoleucine, L-valine and L-lysine oxidation using tiglyl-CoA, 2-methacryl-CoA or crotonyl-CoA, respectively, as a substrate (Fig. 1). 2-Methacrylyl-CoA is a highly reactive compound and readily undergoes reactions with free sulfhydryl groups thereby inactivating important sulfhydryl-containing enzymes such as respiratory chain complexes and pyruvate dehydrogenase complex. Accumulation of 2-methacryl-CoA has been considered as toxic compound in HIBCH deficiency, a disorder of the fifth step of valine oxidation with Leigh-like neurological phenotype and combined deficiency of multiple mitochondrial enzymes (Fig. 1). The neurological phenotypes of individuals with ECHS1 deficiency and HIBCH deficiency are strikingly similar. As ECHS1 is suggested to catalyze the fourth step of valine oxidation, accumulation of 2-methacryl-CoA is expected and may be responsible for some of the pathological changes. Indeed, very recently, ECHS1 mutations were reported in two siblings with Leigh disease and remarkable clinical and biochemical similarities to HIBCH deficiency, with most prominent elevations of methacrylate and acrylate metabolites indicating deficiency of valine oxidation. Our observation of elevated levels of 2-methyl-2,3-dihydroxybutyrate in the urinary organic acids, a likely derivative of valine oxidation metabolites, provides further evidence for the involvement of defective valine metabolism in the pathogenesis of the disease. It may, in addition, be a useful biomarker of disease course as we observed some correlation already with the disease severity. Despite the clinical and biochemical similarities between ECHS1 and HIBCH deficiency, patients with ECHS1 deficiency showed less often impaired oxidative phosphorylation than those with HIBCH deficiency in the investigated fibroblasts or muscle biopsy samples. However, those ECHS1 patients with detectable OXPHOS deficiency had a severe course of disease and died during infancy or early childhood.

In conclusion, the identification of 10 unrelated individuals with ECHS1 mutations allowed us to define the phenotypic spectrum of this new mitochondrial disease entity which can be differentiated clinically and biochemically from other molecular causes of Leigh or Leigh-like syndrome. Regarding pathogenesis, we found both a β-oxidation defect and impaired valine oxidation. We speculate that both defects contribute to the clinical and biochemical phenotype of this newly defined disorder. Intriguingly, ECHS1 deficiency may be amenable to treatment, provided that the elevation of toxic 2-enoyl-CoA compounds can be influenced by dietary intake. All possibly affected amino acids (valine, isoleucine, and lysine) in ECHS1 deficiency are essential amino acids and their dietary uptake can be expected to influence their catabolism. In addition, maintenance of high glucose levels, as recommended in fatty acid oxidation defects might be protective for the heart in ECHS1 deficiency. Anyway, further studies – preferably with an ECHS1 animal model – are necessary to unravel the exact pathomechanisms in ECHS1 deficiency and the efficacy and safety of possible treatments.

Acknowledgments

The authors thank K. Hirano, Y. Endo, T. Matsubayashi, and T. Nagatomo for referral of patient materials and T. Ottlinger for providing the autopsy images. This study was supported by the European Commission (FP7/2007-2013, under grant agreement number 262055 [ESGI], as a Transnational Access project of the European Sequencing and Genotyping Infrastructure); by the German Bundesministerium für Bildung und Forschung (BMBF) through the E-Rare project GENOMIT (01GM1207 for T. M. and H. P. and FWF I 920-B13 for J. A. M.), the German Network for mitochondrial disorders (mitoNET; 01GM1113A to B. B. and T. K., 01GM1113C to T. M., H. P. and P. F., and 01GM1113D to M. S.), the German Mental Retardation Network as part of the National Genome Research to T. M., D. W., and H. E. (grant numbers 01GS08164, 01GS08167, 01GS08163), and the Juniorverbund “mitO-mics” (01ZX1405C); by the Deutsche Forschungsgemeinschaft (SFB 665 C4) to G. S. and M. S.; by a Wellcome Trust Strategic Award (096919/Z/11/Z) and UK NHS Specialized “Rare Mitochondrial Disorders of Adults and Children” Service to R. W. T., a Wellcome Trust WT098051 to R. D.; and by the Novartis Foundation for medical research and the Vinetum Foundation to A. S.; C. L. A. is the recipient of a National Institute of Health Research (NIHR) doctoral fellowship (NIHR-HCS-D12-03-04). This study was supported in part by a grant from the Research Program of Innovative Cell Biology by Innovative Technology (Cell Innovation), a Grant-in-Aid for the Development of New Technology from The Promotion and Mutual Aid Corporation for Private Schools of Japan from MEXT (to Y. O.), Grants-in-Aid for the...
ECHS1 Mutations Cause Encephalocardiomyopathy

T. B. Haack et al.

Research on Intractable Diseases (Mitochondrial Disease) from the Ministry of Health, Labour and Welfare (MHLW) of Japan to A. O. K. M. was supported by Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics. The views expressed are those of the authors and not those of the funding organizations.

Author Contributions


Conflict of Interest

Dr. Cremer, Dr. Engels, Dr. Haack, Dr. Freisinger, Dr. Wieczorek, Dr. Zink, and Dr. Strom report grants from BMBF-German Bundesministerium für Bildung und Forschung during the conduct of the study. Dr. Ohtake reports grants from MHLW-Japanese Ministry of Health, Labour and Welfare, during the conduct of the study; Dr. Alston reports grants from the UK Wellcome Trust, during the conduct of the study. Dr. Durbin reports grants from European Commission, grants from UK Wellcome Trust, during the conduct of the study; other from Congenica Ltd, outside the submitted work. Dr. Eggimann reports grants from Stiftung Batzelbar, outside the submitted work. Dr. Hoffmann reports grants from BMBF-German Bundesministerium für Bildung und Forschung and the Dietmar Hopf Foundation during the conduct of the study. Dr. Murayama reports grants from Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics, during the conduct of the study; Dr. Büchner, Dr. Klopotock, and Dr. Prokisch report grants from European Commission and grants from BMBF-German Bundesministerium für Bildung und Forschung during the conduct of the study. Dr. Nuoffer reports grants from Stiftung Batzelbar, from null, outside the submitted work; Dr. Okazaki reports grants from MEXT-Japanese Ministry of Education, Culture, Sports, Science and Technology, grants from MHLW-Japanese Ministry of Health, Labour and Welfare, during the conduct of the study; Dr. Schaller reports grants from Novartis Foundation, grants from Vinetum Foundation, during the conduct of the study; Dr. Schottmann reports grants from DFG-Deutsche Forschungsgemeinschaft, during the conduct of the study; Dr. Schuinkel reports grants from BMBF-German Bundesministerium für Bildung und Forschung, grants from DFG-Deutsche Forschungsgemeinschaft, during the conduct of the study; Dr. Memari and Dr. Kolb-Kokocinski report grants from European Commission, grants from UK Wellcome Trust, during the conduct of the study. Dr. Mettinger reports grants from European Commission, grants from BMBF-German Bundesministerium für Bildung und Forschung, grants from DFG-Deutsche Forschungsgemeinschaft, during the conduct of the study. Dr Köler reports grants from the European Union, DFG - Deutsche Forschungsgemeinschaft, Kindness-for-Kids Foundation, and Orphan Europe Sarl during the conduct of the study.

References


Supporting Information

Additional Supporting Information may be found in the online version of this article:

Table S1. Annotation details on identified ECHS1 mutations.